169 related articles for article (PubMed ID: 31450973)
1. Momelotinib for the treatment of myelofibrosis.
Xu L; Feng J; Gao G; Tang H
Expert Opin Pharmacother; 2019 Nov; 20(16):1943-1951. PubMed ID: 31450973
[No Abstract] [Full Text] [Related]
2. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
3. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
4. Momelotinib in myelofibrosis.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2024 Apr; 25(5):521-528. PubMed ID: 38623844
[TBL] [Abstract][Full Text] [Related]
5. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
6. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT; Bose P; Verstovsek S
J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
[TBL] [Abstract][Full Text] [Related]
7. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
8. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
9. Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D; Mesa R
Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
[TBL] [Abstract][Full Text] [Related]
10. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
[TBL] [Abstract][Full Text] [Related]
11. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
Mascarenhas J; Mughal TI; Verstovsek S
Curr Med Chem; 2012; 19(26):4399-413. PubMed ID: 22830345
[TBL] [Abstract][Full Text] [Related]
12. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
Saeed I; McLornan D; Harrison CN
Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
14. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Tefferi A; Pardanani A; Gangat N
Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
[TBL] [Abstract][Full Text] [Related]
15. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
[TBL] [Abstract][Full Text] [Related]
16. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
17. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
18. New generation small-molecule inhibitors in myeloproliferative neoplasms.
Passamonti F; Maffioli M; Caramazza D
Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.
Gotlib J
Hematology Am Soc Hematol Educ Program; 2013; 2013():529-37. PubMed ID: 24319228
[TBL] [Abstract][Full Text] [Related]
20. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
